Certara, Inc. $CERT Shares Purchased by Northern Trust Corp

Northern Trust Corp lifted its holdings in Certara, Inc. (NASDAQ:CERT) by 4.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 916,299 shares of the company’s stock after acquiring an additional 39,289 shares during the period. Northern Trust Corp owned approximately 0.56% of Certara worth $9,071,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Wells Fargo & Company MN boosted its position in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. First Trust Advisors LP acquired a new position in shares of Certara during the fourth quarter worth about $140,000. Price T Rowe Associates Inc. MD boosted its position in shares of Certara by 6.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 71,494 shares of the company’s stock worth $762,000 after buying an additional 4,229 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Certara by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock valued at $253,000 after buying an additional 823 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Certara by 60.5% in the fourth quarter. Jane Street Group LLC now owns 236,591 shares of the company’s stock valued at $2,520,000 after buying an additional 89,198 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Price Performance

CERT stock opened at $10.52 on Friday. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $15.69. The stock’s 50 day moving average is $10.80 and its two-hundred day moving average is $11.36. The company has a market capitalization of $1.69 billion, a PE ratio of 210.44 and a beta of 1.43.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The business had revenue of $104.57 million for the quarter, compared to analysts’ expectations of $104.14 million. During the same quarter in the prior year, the firm earned $0.07 earnings per share. Certara’s revenue for the quarter was up 12.1% compared to the same quarter last year. Analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Morgan Stanley assumed coverage on Certara in a report on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 target price on the stock. KeyCorp dropped their target price on Certara from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Monday, July 14th. Finally, UBS Group dropped their target price on Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.